MIST Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Milestone Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$4.05 |
| 52 Week Low | US$1.33 |
| Beta | 1.73 |
| 1 Month Change | -14.12% |
| 3 Month Change | -1.68% |
| 1 Year Change | -62.85% |
| 3 Year Change | -73.65% |
| 5 Year Change | -93.42% |
| Change since IPO | -90.50% |
Recent News & Updates
Recent updates
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Jun 07
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
Apr 02What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
Jan 15First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
Nov 18Milestone Pharmaceuticals EPS beats by $0.09
Nov 13Shareholder Returns
| MIST | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.3% | 2.4% | 0.8% |
| 1Y | -62.8% | 18.3% | 22.5% |
Return vs Industry: MIST underperformed the US Pharmaceuticals industry which returned 18.3% over the past year.
Return vs Market: MIST underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| MIST volatility | |
|---|---|
| MIST Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MIST's share price has been volatile over the past 3 months.
Volatility Over Time: MIST's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 47 | Joe Oliveto | www.milestonepharma.com |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers.
Milestone Pharmaceuticals Inc. Fundamentals Summary
| MIST fundamental statistics | |
|---|---|
| Market cap | US$96.59m |
| Earnings (TTM) | -US$55.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs MIST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIST income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$55.09m |
| Earnings | -US$55.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 126.9% |
How did MIST perform over the long term?
See historical performance and comparison